Skip to main content
GSK
NYSE Life Sciences

GSK to Acquire 35Pharma for $950M, Bolstering Cardiopulmonary Pipeline with HS235

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$59.725
Mkt Cap
$119.729B
52W Low
$32.38
52W High
$61.695
52W Position info
84% above low
Off High info
3.2% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

GSK sits 84% above its 52-week low of $32.38 on light trading volume (0.2× avg).

Summary

GSK announced the acquisition of 35Pharma Inc. for $950 million, adding HS235, a promising clinical-stage asset for cardiopulmonary diseases, to its pipeline.


Key Events · M&A and Partnerships · GSK

  • Acquisition of 35Pharma Inc.

    GSK will acquire 100% of 35Pharma Inc., a clinical-stage biopharmaceutical company, for $950 million in cash.

  • Pipeline Expansion with HS235

    The acquisition includes HS235, a potentially best-in-class activin signalling inhibitor that has completed Phase I trials and is set to begin studies for pulmonary arterial hypertension (PAH) and PH due to heart failure with preserved ejection fraction (PH-HFpEF).

  • Strategic Fit and Market Potential

    HS235 targets a global market for PH therapies forecast to reach $18 billion by 2032 and offers a differentiated profile with reduced bleeding risk and metabolic benefits, bolstering GSK's Respiratory, Immunology and Inflammation portfolio.


Analysis · GSK · Life Sciences

GSK's acquisition of 35Pharma Inc. for $950 million significantly expands its Respiratory, Immunology and Inflammation (RI&I) portfolio. The key asset, HS235, is a clinical-stage activin signalling inhibitor for pulmonary hypertension (PH), a life-shortening disease with a large addressable market. HS235's differentiated profile, including reduced bleeding risk and potential metabolic benefits, positions it as a potentially best-in-class therapy. This strategic move enhances GSK's long-term growth prospects in a high-value therapeutic area.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GSK was trading at $59.73 on NYSE in the Life Sciences sector, with a market capitalization of approximately $119.7B. The 52-week trading range was $32.38 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GSK - Latest Insights

GSK
Oct 28, 2026, 11:45 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $48.75
Real-time Price: $50.62 info
Change: +$1.87 (+4%) info
Market Cap: $102.527B info
GSK
Oct 28, 2026, 10:45 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $49.08
Real-time Price: $50.62 info
Change: +$1.54 (+3%) info
Market Cap: $102.527B info
GSK
Oct 28, 2026, 3:42 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $51.20
Real-time Price: $50.62 info
Change: -$0.580 (-1%) info
Market Cap: $102.527B info
GSK
Oct 26, 2026, 12:16 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $51.12
Real-time Price: $50.62 info
Change: -$0.495 (-0.97%) info
Market Cap: $102.527B info
GSK
Oct 26, 2026, 6:51 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $51.04
Real-time Price: $50.62 info
Change: -$0.420 (-0.82%) info
Market Cap: $102.527B info